Arriving in the landscape of obesity management, retatrutide presents a unique strategy. Beyond many available medications, retatrutide works as a dual agonist, simultaneously engaging both GLP peptide-1 (GLP-1) and glucose-dependent insulinotropic substance (GIP) binding sites. The dual stimulation fosters various advantageous effects, like enhanc